CRIS Current Research Information System

BOCHICCHIO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.573
NA - Nord America 2.572
EU - Europa 1.880
SA - Sud America 142
Continente sconosciuto - Info sul continente non disponibili 142
AF - Africa 141
OC - Oceania 4
Totale 7.454
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.523
VN - Vietnam 673
SG - Singapore 670
CN - Cina 619
GB - Regno Unito 403
IT - Italia 393
SE - Svezia 248
DE - Germania 213
HK - Hong Kong 174
FR - Francia 121
NL - Olanda 120
IN - India 116
BR - Brasile 95
RU - Federazione Russa 94
KR - Corea 68
IE - Irlanda 63
JP - Giappone 49
BD - Bangladesh 47
FI - Finlandia 40
ZA - Sudafrica 39
JO - Giordania 38
TG - Togo 34
EE - Estonia 32
CA - Canada 28
BG - Bulgaria 26
CH - Svizzera 25
UA - Ucraina 25
NG - Nigeria 23
PH - Filippine 23
CI - Costa d'Avorio 19
AR - Argentina 16
ES - Italia 16
BE - Belgio 15
ID - Indonesia 15
AT - Austria 14
TH - Thailandia 14
SC - Seychelles 13
MX - Messico 12
TW - Taiwan 12
EC - Ecuador 11
TR - Turchia 10
PL - Polonia 8
IR - Iran 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
IQ - Iraq 5
VE - Venezuela 5
AU - Australia 4
CL - Cile 4
PY - Paraguay 4
RO - Romania 4
CO - Colombia 3
CZ - Repubblica Ceca 3
GR - Grecia 3
JM - Giamaica 3
LB - Libano 3
LT - Lituania 3
MK - Macedonia 3
MY - Malesia 3
PE - Perù 3
PT - Portogallo 3
TN - Tunisia 3
BA - Bosnia-Erzegovina 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
IL - Israele 2
MA - Marocco 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
GM - Gambi 1
HR - Croazia 1
KE - Kenya 1
KG - Kirghizistan 1
LY - Libia 1
MN - Mongolia 1
MQ - Martinica 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SN - Senegal 1
SV - El Salvador 1
Totale 7.314
Salva come PNG Salva come JPEG
Città #
Singapore 475
Southend 362
Ashburn 278
Chandler 251
Fairfield 182
San Jose 175
Hong Kong 163
Ho Chi Minh City 149
Hefei 122
Dong Ket 120
Hanoi 119
Ann Arbor 111
Houston 100
Beijing 89
Wilmington 81
Seattle 80
Woodbridge 79
Princeton 78
Bologna 71
Cambridge 70
New York 67
Boardman 64
Dublin 63
Santa Clara 63
Seoul 55
Nanjing 48
Lauterbourg 42
Tokyo 42
Los Angeles 40
Amman 38
Lomé 34
Westminster 33
Dallas 31
Padova 31
Milan 28
Buffalo 26
Haiphong 26
Helsinki 26
Sofia 26
Medford 24
Munich 24
Abeokuta 21
Da Nang 21
Bern 20
Jinan 20
Shenyang 20
São Paulo 20
Abidjan 19
Frankfurt am Main 18
Rome 18
Berlin 16
Bremen 16
Brussels 15
Hebei 15
Shanghai 15
Redondo Beach 14
Saint Petersburg 12
Turin 12
Bengaluru 11
Biên Hòa 11
Chicago 11
Council Bluffs 11
Redmond 11
Tianjin 11
Hải Dương 10
Jakarta 10
London 10
Redwood City 10
Can Tho 9
Guangzhou 9
Jiaxing 9
Montreal 9
Nanchang 9
Norwalk 9
Phoenix 9
Salamanca 9
Johannesburg 8
Nuremberg 8
San Diego 8
Vienna 8
Amsterdam 7
Changsha 7
Florence 7
Paris 7
Shijiazhuang 7
Turku 7
Bắc Giang 6
Castel Maggiore 6
Falkenstein 6
Hangzhou 6
Lappeenranta 6
Monza 6
Torino 6
Toronto 6
Bangkok 5
Bühl 5
Bến Tre 5
Dearborn 5
Granarolo dell'Emilia e Viadagola 5
Mexico City 5
Totale 4.608
Salva come PNG Salva come JPEG
Nome #
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 234
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 232
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 232
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 219
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 216
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 208
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 201
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 185
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 184
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 183
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 181
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 178
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 178
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 174
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 173
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 168
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 166
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 165
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 162
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 160
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 160
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 155
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 154
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 153
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 151
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 150
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 147
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients 145
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 144
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 143
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 141
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 139
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 138
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 138
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 133
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 132
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 129
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukaemia 125
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 119
Differences among young adults, adults and elderly chronic myeloid leukemia patients 118
null 81
IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease 42
Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma 13
Totale 7.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.138
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.138
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022750 43 11 53 77 72 41 16 42 45 71 136 143
2022/2023903 100 125 37 121 69 64 27 60 177 15 62 46
2023/2024290 7 42 21 30 20 72 11 18 23 8 18 20
2024/20251.005 39 132 74 75 103 40 99 30 18 135 44 216
2025/20262.740 219 232 243 176 276 117 316 86 670 190 126 89
2026/202794 94 0 0 0 0 0 0 0 0 0 0 0
Totale 7.454